International Stem Cell (ISCO) Current Assets (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Current Assets of $3.4 million for Q4 2025, down 4.19% year-over-year from $3.6 million in Q4 2024, and down 8.65% quarter-over-quarter from $3.7 million in Q3 2025.
International Stem Cell (ISCO) Current Assets (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Current Assets for 16 consecutive years, with $3.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets fell 4.19% year-over-year to $3.4 million; the TTM figure through Dec 2025 stood at $3.4 million (down 4.19% YoY), while the FY2025 annual figure was $3.4 million, down 4.19% from the prior year.
- Current Assets declined to $3.4 million in Q4 2025 per ISCO's latest filing, from $3.7 million in the prior quarter.
- Across five years, Current Assets topped out at $3.8 million in Q2 2025 and bottomed at $2.3 million in Q4 2021.
- Historically, Current Assets has averaged $3.3 million across 5 years, with a median of $3.5 million in 2024.
- Annual changes were most pronounced in 2021 — Current Assets slipped 18.01% — and 2023, when it soared 35.48%.
- International Stem Cell's Current Assets stood at $2.3 million in 2021, then gained by 26.95% to $3.0 million in 2022, then grew by 18.83% to $3.5 million in 2023, then rose by 1.11% to $3.6 million in 2024, then fell by 4.19% to $3.4 million in 2025.
- Business Quant data shows ISCO's Current Assets at $3.4 million in Q4 2025, $3.7 million in Q3 2025, and $3.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 3.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.92 Mn |
| Dec 31, 2025 | 3.41 Mn |
| Sep 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.84 Mn |
| Mar 31, 2025 | 3.84 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Sep 30, 2024 | 3.49 Mn |
| Jun 30, 2024 | 3.82 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Dec 31, 2023 | 3.52 Mn |
| Sep 30, 2023 | 3.66 Mn |
| Jun 30, 2023 | 3.68 Mn |
| Mar 31, 2023 | 3.24 Mn |
| Dec 31, 2022 | 2.96 Mn |
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 2.99 Mn |
| Mar 31, 2022 | 2.96 Mn |
| Dec 31, 2021 | 2.33 Mn |
| Sep 30, 2021 | 2.49 Mn |
| Jun 30, 2021 | 2.79 Mn |